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Effect of dietary advanced glycation 
end products on inflammation 
and cardiovascular risks in healthy 
overweight adults: a randomised 
crossover trial
Estifanos Baye1, Maximilian PJ de Courten2, Karen Walker3, Sanjeeva Ranasinha1, Arul 
Earnest4, Josephine M Forbes5,6 & Barbora de Courten1,7
Diets high in advanced glycation end products (AGEs) are thought to be detrimental to cardiovascular 
health. However, there remains uncertainty about the beneficial effect of a low AGE diet on 
cardiovascular risk factors and inflammatory markers in overweight individuals. We thus performed 
a randomised, double blind, crossover trial to determine whether consumption of low AGE diets 
reduce inflammation and cardiovascular risks in overweight and obese otherwise healthy adults. 
All participants (n = 20) consumed low and high AGE diets alternately for two weeks and separated 
by a four week washout period. Low AGE diets did not change systolic (p = 0.2) and diastolic blood 
pressure (p = 0.3), mean arterial pressure (p = 0.8) and pulse pressure (p = 0.2) compared to high AGE 
diets. Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein 
(p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory 
markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor 
α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2). These findings indicate 
that consumption of low AGE diets for two weeks did not improve the inflammatory and cardiovascular 
profiles of overweight and obese adults.
Advanced glycation end products (AGEs) are formed endogenously from non-enzymatic reactions of amino 
acids with sugars1. Consumption of foods high in sugar and/or foods exposed to high temperature cooking meth-
ods such as deep-frying, broiling, roasting, baking and grilling can increase the total daily AGE intake by 25% 
compared to the average adult daily intake2, 3. High AGE intake from food accelerates the production of endoge-
nous AGEs and increases the level of circulating AGEs in the blood stream4, 5. This intake of high AGE contributes 
to the progression of type 2 diabetes (T2DM) and cardiovascular diseases (CVD) although the exact mechanisms 
are not clearly understood6–11. AGE formation can be reduced by shortening the cooking time and lowering tem-
perature to reduce food browning, or by addition of acidic (low pH) ingredients and by high humidity or food 
moisture content7, 12. Given the ease of such changes, reduction of AGE intake may be a promising intervention 
to lower cardiovascular risk3, 13–15.
In humans, the impact of low AGE diets on inflammation and cardiovascular risk factors is not clearly under-
stood. In some studies involving healthy obese individuals, low AGE diets reduced inflammatory markers11, 16, 17 
but did not change plasma lipid levels17, 18 or blood pressure17, 19. Whereas, other studies showed a reduction in 
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plasma lipid levels after low AGE diets19–21 but not of markers of inflammation18, 22. In patients with T2DM, low 
AGE diets improved inflammatory markers6, 8, 9, but not blood pressure9, and lipid levels6, 9. Cai and colleagues 
however reported a reduction in oxidised low-density lipoprotein after 6 weeks of consumption of low AGE diets 
(5 fold lower in AGE content) in patients with T2DM23. In all these studies, test and control diets were either not 
matched for energy and macronutrient content or it was not stated whether similar macronutrient content was 
achieved between the diets, which could potentially influence the results24. We have therefore investigated the 
impact of low and high AGE diets carefully matched for both energy and macronutrient profile. These matched 
diets were given for two weeks each to healthy obese adults in a randomised cross-over design trial to determine 
effects on cardiometabolic parameters. We have previously reported the main outcomes of the trial which showed 
that dietary AGEs improved insulin sensitivity but not insulin secretion in overweight and obese non-diabetic 
individuals24. In this study, we conducted analyses of secondary outcomes of the trial and investigated if dietary 
AGEs improve blood pressure, plasma lipid profiles and inflammatory markers.
Results
Baseline characteristics. As previously described24, the mean age, body mass index, waist-to-hip ratio and 
% body fat of the participants were 34 (10) years, 31.3 (3.8) kg/m2, 0.9 (0.1) and 31.1 (6.7), respectively. There 
was no difference in levels of circulating AGEs and metabolic profiles such as insulin sensitivity and secretion 
between group 1 and 2 before each test diet24. Anthropometric and blood pressure measurements, plasma lipid 
levels and inflammatory markers were also not different between the two interventions at the beginning of each 
dietary period (Table 1). The cumulative dietary AGE intakes were significantly lower in the low AGE dietary 
period compared to the high AGE dietary period (all p < 0.002), as reported previously24. The mean consumption 
of carboxymethyllysine, carboxyethyllysine and methylglyoxal-derived hydroimadazolidine were decreased by 
27%, 38%, and 21%, respectively, in the low AGE group compared to the high AGE group.
Effect of low AGE diet on inflammatory markers. Inflammatory markers such as tumour necrosis 
factor α (TNF α), C-reactive protein (CRP), monocyte chemoattractant protein 1 (MCP-1) and interleukin 6 
(IL-6) levels and nuclear factor kappa beta (NFκβ) activity in peripheral blood mononuclear cells (PBMCs) did 
not change after consumption of either low or high AGE diets. Between groups comparison also showed that the 
changes in these markers were not significantly different between low and high AGE diets (Table 2).
Effect of low AGE diets on cardiovascular parameters. Anthropometric measures such as weight and 
body mass index were significantly reduced only in the low AGE group compared to high AGE group. Percentage 
body fat and waist-to-hip ratio did not change after consumption of either diet. Between groups comparison 
have shown that none of these anthropometric measures were different between the diets (Table 2). Systolic and 
diastolic blood pressure and mean arterial pressure decreased after consumption of both diets whereas pulse pres-
sure was reduced only after intake of low AGE diets. Between groups analyses (after controlling for period and 
sequence effect) did not show any significant change in these measurements between the diets (Table 2).
The total plasma cholesterol levels decreased in both groups, however, the change between the two diets was 
not significant. Both plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels 
Parameters Low AGE group High AGE group P-value
Weight (kg) 94.2 ± 15.2 94.1 ± 14.3 0.94
Body mass index (kg/m2) 31.4 ± 3.8 31.3 ± 3.7 0.85*
% body fat 30.7 ± 6.5 30.6 ± 6.6 0.83
Waist-to-hip ratio 0.9 ± 0.07 0.9 ± 0.07 0.35*
Systolic BP (mm Hg) 123.1 ± 10.8 122.3 ± 12.3 0.66
Diastolic BP (mm Hg) 77.9 ± 8.9 76.7 ± 9 0.38
Mean arterial pressure (mm Hg) 92.9 ± 9.1 91.9 ± 9 0.37
Pulse pressure (mm Hg) 45.1 ± 6.4 45.6 ± 10.1 0.90*
Total cholesterol (mmol/l) 4.8 ± 1 4.6 ± 1 0.06
LDL (mmol/l) 3.1 ± 0.8 3.1 + 0.7 0.61
HDL (mmol/l) 1 ± 0.2 1 ± 0.2 0.35
Triglycerides (mmol/l) 1.5 ± 1 1.3 ± 0.7 0.11*
CRP (mg/l) 2.1 ± 1.9 2.4 ± 2.7 0.69*
TNFα (pg/ml) 2.8 ± 3.7 1.6 ± 0.9 0.18
MCP-1 (pg/ml) 126 ± 99 121 ± 66 0.92*
IL-6 (ng/ml) 1.5 ± 2.2 1.6 ± 2.4 0.64*
NFκβ p65 activity (ng/µg protein) 14 ± 10 12 ± 10 0.53
Table 1. Participants’ baseline characteristics at the beginning of each study period (n = 20). All values are 
presented as means ±SDs. Paired t-tests were conducted to determine the p-values. *Data transformation was 
done. BP, blood pressure; CRP, C-reactive protein; HDL, high-density lipoprotein; IL-6, interleukin -6; LDL, 
low-density lipoprotein; MAP, mean arterial pressure; MCP-1, monocyte chemoattractant protein-1; NFκβ; 
Nuclear factor kappa beta; PP, pulse pressure.
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decreased with low AGE diet but not changed with high AGE diet whereas the overall difference between the diets 
was not significant (Table 2). Plasma triglyceride levels decreased with high AGE diet but there was no difference 
between low and high AGE diets (Table 2).
Correlation analyses between inflammation markers and anthropometric measures and cardi-
ovascular risk factors. The correlation analyses indicated that the change in diastolic blood pressure and 
MCP-1 is positively correlated with % body fat (r = 0.43, p = 0.05) and waist-to-hip ratio (r = 0.46, p = 0.03), 
respectively. Change in systolic blood pressure is also positively correlated with NFκβ (r = 0.47, p = 0.04) 
whereas plasma lipid levels negatively correlate with CRP (total cholesterol: r = −0.53, p = 0.01; HDL: r = −0.59, 
p = 0.006; LDL: r = −0.56, p = 0.008) and IL-6 (total cholesterol: r = −0.51, p = 0.03; HDL: r = −0.58, p = 0.01; 
LDL: r = −0.54, p = 0.01). After adjusting either for change in weight, body mass index, % body fat or waist-to-hip 
ratio, neither systolic blood pressure nor lipid parameters correlated with inflammatory markers. Other inflam-
mation parameters did not show any correlation with cardiovascular parameters (all p > 0.1). Circulating and 
urinary AGE levels also did not correlate with any cardiovascular parameters (all p > 0.09).
Discussion
The present study aimed to measure the effect of consuming low AGE diets for 2 weeks on markers of inflamma-
tion and cardiovascular risk factors in healthy obese and overweight individuals. No significant difference was 
found in changes in blood pressure, plasma lipid levels (total cholesterol, LDL, HDL, triglycerides) or inflamma-
tory markers (CRP, TNFα, MCP-1, IL-6, NFκβ activity) between low and high AGE diets. Our findings on blood 
pressure measurements were consistent with other studies conducted in healthy overweight individuals17, 19, 
prediabetes21, obese people with metabolic syndrome25, 26, and patients with T2DM9.
Regarding plasma lipid profile, we did not find a significant difference between low and high AGE diets. Some 
studies conducted in healthy individuals17, 18, obese individuals with metabolic syndrome25, 26, and patients with 
T2DM6, 9 have also reported that consumption of low AGE diets did not change plasma lipid levels compared 
to high AGE diets. In contrast, two other studies that involved young healthy obese volunteers20 and predia-
betic individuals21 noted a reduction in plasma lipid levels after a low AGE diet. In the first study, the difference 
between the 2 diets could have been due to the higher intake of dietary fat and carbohydrate on the high AGE 
diets20. The patients in the second trial in the low AGE arm of the study had relatively lower intima-media thick-
ness compared to those who were in the high AGE diet21. This may exaggerated the effect of high AGE diets on 
lipid profile. In addition, consumption of low AGE diets combined with aerobic exercise program for 12 weeks 
showed a decrease in plasma lipid levels in overweight and obese men19. This effect however could have been due 
to the synergistic effect of physical activity with low AGE diets as it has been widely known for its beneficial effect 
on metabolic changes27. Therefore, these studies19–21 were not able to differentiate between the true effect of low 
and high AGE diet as they were confounded by other differences in diet, exercise or disease state of the patients.
Parameters
Change from baseline in low 
AGE group
Change from baseline in high 
AGE group Difference between the groups
Mean ± SD P-value† Mean ± SD P-value† Mean ± SD P-value††
Weight (kg) −0.69 ± 1.34 0.03 −0.16 ± 1.17 0.54 −0.52 ± 1.52 0.17
BMI (kg/m2) −0.22 ± 0.45 0.03 −0.06 ± 0.38 0.49 −0.16 ± 0.5 0.20
% body fat −0.06 ± 1.2 0.82 −0.08 ± 1.39 0.80 +0.02 ± 1.56 0.37
WHR +0.004 ± 0.03 0.55 −0.004 ± 0.032 0.54 +0.008 ± 0.031 0.49
Systolic BP (mm Hg) −1.2 ± 7.7 0.49 −1.3 ± 8.3 0.47 +0.1 ± 11.4 0.24
Diastolic BP (mm Hg) −0.8 ± 8.4 0.67 −1.9 ± 6.2 0.18 +1.1 ± 11.6 0.33
Pulse Pressure (mm Hg) −0.4 ± 7.7 0.81 +0.5 ± 9.7 0.80 −0.9 ± 9.2 0.16
MAP (mm Hg) −0.9 ± 7.3 0.57 −1.7 ± 5.2 0.16 +0.8 ± 10.7 0.80
Total cholesterol (mmol/l) −0.4 ± 0.5 0.0006 −0.15 ± 0.3 0.04 −0.3 ± 0.6 0.26
LDL (mmol/l) −0.3 ± 0.3 0.002 −0.01 ± 0.3 0.86 −0.3 ± 0.5 0.73
HDL (mmol/l) −0.06 ± 0.1 0.03 −0.008 ± 0.08 0.66 −0.05 ± 0.1 0.21
Triglycerides (mmol/l) −0.1 ± 0.3 0.08 −0.2 ± 0.3 0.01 +0.04 ± 0.5 0.44
IL-6 (ng/ml) −0.4 ± 1.9 0.71* −0.2 ± 1.8 0.94* −0.2 ± 2.9 0.62*
MCP-1 (pg/ml) −5.4 ± 37.4 0.52 +1.9 ± 44.6 0.84 +7.41 ± 65.8 0.94
TNFα (pg/ml) −0.4 ± 4.4 0.84* +1.8 ± 5.5 0.16* −2.2 ± 7.1 0.15*
CRP (mg/l) +0.08 ± 0.66 0.57 +0.19 ± 1.55 0.57 +0.1 ± 1.6 0.60
NFκB p65 activity (ng/µg protein) −3.4 ± 9.9 0.14 −1.3 ± 11.4 0.61 −2.1 ± 16.7 0.18
Table 2. Effects of low and high AGE diets on markers of inflammation and cardiovascular risk factors (n = 20). 
†Paired t-tests were conducted to determine the p-values within each groups. ††A 2 × 2 ANOVA for cross over 
study was used to determine the overall difference between the diets. *Data transformation was done. BP, blood 
pressure; CRP, C-reactive protein; HDL, high-density lipoprotein cholesterol; IL-6, interleukin -6; LDL, low-
density lipoprotein; MAP, mean arterial pressure; MCP-1, monocyte chemoattractant protein-1; NFκβ; nuclear 
factor kappa B; SD, standard deviation.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 4123  | DOI:10.1038/s41598-017-04214-6
In this study, intake of low AGE diets for 2 weeks did not change inflammatory markers. This finding was con-
sistent with some studies conducted in healthy overweight and obese individuals18, 22. Other studies conducted 
in healthy individuals showed an improvement in inflammatory markers after intake of low AGE diets11, 16, 17. 
However, in these studies, the diets were not matched for macronutrient content, which might have influenced 
the findings. Studies in obese people with metabolic syndrome26, prediabetes21 and patients with T2DM8, 9 showed 
an improvement in inflammatory markers after intake of low AGE diets compared to high AGE diets. Therefore, 
it could be suggested that intake of low AGE diets was beneficial for those who had higher baseline values in 
inflammatory markers such as patients with metabolic syndrome or T2DM.
Compared to the previous studies, our study has several strengths that include standardised diets in energy 
and macronutrient content were provided, study personnel including the investigators were unaware of the die-
tary allocation, and baseline characteristics such as anthropometric, circulating AGEs and metabolic parameters 
were not different at baseline during each dietary period. We have also used a crossover design to control for 
possible confounding factors in addition to the rigorous randomisation process. The small sample size and rel-
atively short duration could be considered as main limitations of this study as one can argue that the change in 
physiologic processes after intake of low AGE diets may require longer duration.
In conclusion, we have shown that consumption of low AGE diets for 2 weeks did not have beneficial effects 
in reducing markers of inflammation and cardiovascular risk factors in healthy overweight and obese adults. 
Long-term well designed trials with larger sample sizes are needed to confirm our findings.
Methods
Study participants. Twenty overweight and obese but otherwise healthy and normoglycemic adults, aged 
18–50 years completed the study24, according to a protocol as previously published elsewhere28. Participants 
did not have diabetes as indicated by a 75 g oral glucose tolerance test (OGTT) (WHO 1999 criteria). All were 
non-smokers and had no clinical and laboratory signs of infection and none took supplements/medications 
during the study period. The participants were recruited from the general community through advertisements 
between January 2006 and December 2010. Ethical approval was obtained from the Alfred Hospital Ethics 
Committee, Melbourne, Australia and complied with the Declaration of Helsinki. All participants provided writ-
ten informed consent prior to participation.
Study design. This study employed a two-period randomised cross-over double-blind design. All partici-
pants underwent both diets; one low in AGE content and one high in AGE content (typical of a modern Western 
diet) and diets were matched in energy and macronutrient content. Participants commenced the study after a 
two-week run-in on their habitual diet but with limitation of their alcohol, fast food and coffee intake. Test diets 
were consumed for two weeks separated by a four-week washout period (habitual diet). The primary outcomes of 
this study that focused on insulin resistance/sensitivity have been published24.
Randomisation and masking. Randomisation occurred for 7 blocks of 4 participants stratified by gender 
and diet order. Participants were masked to the allocation of diet type and to how the diet might affect glucose 
metabolism. Clinical and laboratory investigators were also masked to diet allocation.
Study Procedures. All participants underwent medical and laboratory screening including a 75 g oral glu-
cose tolerance test (OGTT). Prior to metabolic testing, participants were asked to abstain from strenuous exercise 
and caffeine for 3 days.
Dietary Intervention. Prior to starting the ‘run-in’ to the first diet, participants kept a 3-day diet record 
of their habitual diet (2 weekdays, 1 weekend day) based on household measures. Nutrient content was ana-
lysed with SERVE (SERVE Nutrition Systems, St Ives, NSW), based on Australian food composition tables. 
With the use of Australian food composition data from SERVE as well as data from the United States on the N 
(ε)-carboxymethyllysine (CML – the most common AGEs used in clinical studies as an indicator of dietary AGE 
intake) content of common foods, a menu of carefully matched alternative food choices (of low AGE vs high AGE 
content) individualised to suit the preferences and habitual diet of each participant was designed. These alter-
native food choices were matched for macronutrient content and total energy but greatly differed in calculated 
AGE content, and were provided for each meal of the day, including snacks and beverages. Food choices on the 
high AGE diet had higher dietary AGE content, while the isoenergetic low AGE diet, matched for macronutrient 
content, had reduced AGE content through altered cooking techniques4 and use of differently processed foods. 
All food for the two test diets was provided weekly to the participants as ready-to-eat items or as packed food 
portions, to assist with dietary compliance. For food that required cooking, detailed instructions for storage and 
heating (method, temperature, and duration) were provided. Participants were asked to eat to appetite through-
out both dietary periods to maintain constant body weight. They were required to keep a detailed dietary record 
indicating cooking method and number of portions eaten for each food item supplied, unconsumed foods or 
additional foods eaten. Later foods incorporated in these diets were also chemically analysed for their AGE con-
tent. The dietician made telephone contact twice a week to provide support and resolve difficulties as well as to 
ensure dietary compliance. To analyse the dietary AGE content, food items were obtained from local supermar-
kets and prepared according to the instructions provided to the participants in the study.
Cardiovascular measures. Systolic and diastolic blood pressure were measured using an automated oscil-
lometric measurement system (Omron) after a 30 minute rest. Pulse pressure was calculated by subtracting the 
diastolic blood pressure from the systolic blood pressure. Mean arterial pressure was computed as diastolic blood 
pressure + pulse pressure/329. Plasma lipid levels such as total cholesterol, LDL, HDL and triglycerides were 
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measured using a standard commercial enzymatic assay (Beckman Coulter LX20PRO Analyser and Synchron) 
and Systems Lipid and Multi Calibrators (Beckman Coulter Diagnostics).
Measurement of inflammatory markers and AGEs. Markers of inflammation (TNFα, MCP-1 and 
IL-6 levels) were analysed using a commercial automated chemiluminescent enzyme immunoassay and immulite 
analyser (Diagnostic Products Corporation). Whereas, highly sensitive near infrared particle immunoassay rate 
methodology was used to measure plasma CRP levels. NFκβ activity in PBMCs was detected and quantified using 
TransAM NF- κβ DNA-binding activity assay (Active Motif, Carlsbad, CA, USA). Measurement of urinary and 
serum AGEs were quantified with the use of ultraperformance liquid chromatography–tandem mass spectrom-
etry as previously described30.
Statistical analysis. Change from baseline values was calculated for each parameter in both dietary peri-
ods. Paired t-tests were used to compare the participants’ characteristics at the beginning of each dietary period 
and to determine the change in parameters after each study diet. Repeated measures ANOVA was employed 
to determine the change difference between the two diets after adjusting for carryover, sequence and period 
effects. The observed carryover effect in this study was very minimal (29.8%) and thus the data in both study 
periods were combined. Results are presented using means and standard deviations unless and otherwise stated. 
Appropriate data transformation was undertaken in the event of skewed data to approximate a normal distribu-
tion. Statistical analyses were performed using Stata 14 software. P-value of ≤ 0.05 is used to describe statistical 
significant difference.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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